Evidence map›Paper›PMID 34378086›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021

Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19.

Maddalena Peghin, Emilio Bouza, Martina Fabris, Maria De Martino, Alvisa Palese, Giulia Bontempo, Elena Graziano, Valentina Gerussi, Valentina Bressan, Assunta Sartor and 3 more

Abstract read
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Medicina (Kaunas, Lithuania) · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maddalena PeghinInfectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Presidio Ospedaliero Universitario Santa Maria della Misericordia Piazzale Santa Maria della Misericordia 15 33010, Udine, Italy. maddalena.peghin@gmail.com.ORCID http://orcid.org/0000-0002-4640-679X
Emilio BouzaDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Martina FabrisInstitute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC, Udine, Italy.
Maria De MartinoDivision of Medical Statistics, Department of Medicine (DAME), University of Udine 33100, Udine, Italy.
Alvisa PaleseDepartment of Medical Sciences, School of Nursing, University of Udine 33100, Udine, Italy.
Giulia BontempoInfectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Presidio Ospedaliero Universitario Santa Maria della Misericordia Piazzale Santa Maria della Misericordia 15 33010, Udine, Italy.
Elena GrazianoInfectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Presidio Ospedaliero Universitario Santa Maria della Misericordia Piazzale Santa Maria della Misericordia 15 33010, Udine, Italy.
Valentina GerussiInfectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Presidio Ospedaliero Universitario Santa Maria della Misericordia Piazzale Santa Maria della Misericordia 15 33010, Udine, Italy.
Valentina BressanDepartment of Medical Sciences, School of Nursing, University of Udine 33100, Udine, Italy.
Assunta SartorInstitute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC, Udine, Italy.
Miriam IsolaDivision of Medical Statistics, Department of Medicine (DAME), University of Udine 33100, Udine, Italy.
Carlo TasciniInfectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Presidio Ospedaliero Universitario Santa Maria della Misericordia Piazzale Santa Maria della Misericordia 15 33010, Udine, Italy.
Francesco CurcioInstitute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC, Udine, Italy.

Funding

This research was funded by PRIN 2017 n.20178S4EK9 ‒ "Innovative statistical methods in biomedical research on biomarkers: from their identification to their use in clinical practice This research was funded by PRIN 2017 n.20178S4EK9 ‒ "Innovative statistical methods in biomedical research on biomarkers: from their identification to their use in clinical practice".
6 · The paper itself

Abstract

The aim of the study was to assess reinfection rates in relation to long-term antibody dynamics against SARS-CoV-2 after the first wave. A prospective longitudinal study with monthly serological follow-up during the first 4 months, and then at 6, 8, and 10 months after the disease onset of all recovered adult in- and outpatients with COVID-19 attending Udine Hospital (Italy) from March to May 2020. During the follow-up, reinfections were collected. A total of 546 unselected individuals with COVID-19 acquired from March to May 2020 were included (292 female, mean age 53 years). After a median follow-up of 10 months (IQR 6.2-10.4), reinfection occurred in 6 (1.1%) patients, median age of 44.5 years (IQR 33‒49). All had a previous history of mild COVID-19 (all were healthcare workers) and reinfection occurred a median of 9 months (IQR 8.2‒10.2) after the onset of the first episode. Patients with reinfection were either seronegative (2/56, n = 3.6%), seroreverted (2/137, 1.5%), or seropositive (2/353, 0.6%) (p = 0.085). All reinfections were mild (n = 5) or asymptomatic (n = 1). After reinfection, none of patients developed IgM response and only two had a transitory boosted IgG immunization response. In an unselected population after the first wave of COVID-19, after a prolonged observation period (mean 10 months), reinfection was very uncommon; occurred in patients with a previous history of mild infection, mostly with weak or absent serological response; and manifested with mild or asymptomatic clinical presentation.

Indexed as

AdultAntibodies, ViralCOVID-19FemaleFollow-Up StudiesHumansImmunoglobulin GImmunoglobulin MLongitudinal StudiesMaleMiddle AgedProspective StudiesReinfectionSARS-CoV-2Antibodies, ViralImmunoglobulin GImmunoglobulin MCOVID-19 reinfectionLongitudinal studySARS-CoV-2 antibodiesSARS-CoV-2 IgGSARS-CoV-2 IgMSARS-CoV-2 reinfectionSARS-CoV-2 serology

Identifiers

PMID34378086
PMCPMC8354681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.